PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Practice Signal

Checkpoint Inhibitors Beyond GI Cancers: Setting Matters

This review helps pharmacists match checkpoint inhibitor orders to the settings, biomarkers, and regimens that carry survival evidence, and frame the risks of restarting therapy after an irAE.

Bottom Line

Programmed cell death 1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitor benefit in triple-negative breast, cervical, and resectable head and neck cancers depends on disease setting, PD-L1 selection, and the exact trial regimen, while rechallenge after an immune-related adverse event (irAE) carries roughly a one-in-five risk of grade 3 or higher toxicity and calls for deliberate counseling.

0.64
OS HR, early-stage TNBC
0.70
EFS HR, KEYNOTE-689 CPS ≥ 1
28.7 vs 19.4
median OS months, cervical
25.3%
discontinuation after ICI rechallenge

State of Play

Immune checkpoint inhibitors (ICIs) added to standard therapy now hold a defined place in early-stage and PD-L1-positive metastatic triple-negative breast cancer (TNBC), first-line recurrent or metastatic cervical cancer, and resectable locally advanced head and neck squamous cell carcinoma (HNSCC). Across these cancers the evidence is most robust where randomized trials directly support a specific regimen, and weaker where pooled estimates stretch across heterogeneous populations or partner drugs.

🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.

Subscribe for $8/month →
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.
pembrolizumab atezolizumab nivolumab ipilimumab bevacizumab nab-paclitaxel paclitaxel carboplatin PD-1 inhibitors PD-L1 inhibitors immune checkpoint inhibitors triple-negative breast cancer
🎓
Synthesized and reviewed by a licensed pharmacist
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.
Thanks for the feedback!

← Back to Evidence Rounds